Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma ( LBCL): Primary Analysis of a Phase Ib/II Study

被引：7

作者：

Budde, L. Elizabeth ^{[1
]}

Olszewski, Adam J. ^{[2
]}

Assouline, Sarit ^{[3
]}

Lossos, Izidore S. ^{[4
]}

Diefenbach, Catherine ^{[5
]}

Kamdar, Manali ^{[6
]}

Ghosh, Nilanjan ^{[7
]}

Modi, Dipenkumar ^{[8
]}

Sabry, Waleed ^{[9
]}

Naik, Seema ^{[10
]}

Mehta, Amitkumar ^{[11
]}

Nakhoda, Shazia K. ^{[12
]}

Smith, Stephen D. ^{[13
]}

Dorritie, Kathleen ^{[14
]}

Jia, Ting ^{[15
]}

Pham, Song ^{[16
]}

Huw, Ling-Yuh ^{[17
]}

Wu, Hao ^{[17
]}

To, Iris ^{[17
]}

Wei, Michael C. ^{[17
]}

Chavez, Julio C. ^{[18
]}

机构：

[1] City Hope Natl Med Ctr, Duarte, CA USA

[2] Brown Univ, Lifespan Canc Inst, Legorreta Canc Ctr, Providence, RI USA

[3] McGill Univ, Jewish Gen Hosp, Montreal, PQ, Canada

[4] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA

[5] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA

[6] Univ Colorado, Aurora, CO USA

[7] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA

[8] Wayne State Univ, Barbara Ann Karmanos Canc Inst, Detroit, MI USA

[9] Univ Saskatchewan, Saskatoon Canc Ctr, Coll Med, Saskatoon, SK, Canada

[10] Penn State Canc Inst, Hershey, PA USA

[11] Univ Alabama Birmingham, Birmingham, AL USA

[12] Fox Chase Canc Ctr, Philadelphia, PA USA

[13] Univ Washington, Fred Hutchinson Canc Ctr, Seattle, WA USA

[14] Univ Pittsburgh, UPMC Hillman Canc Ctr, Pittsburgh, PA USA

[15] Roche China Holding Ltd, Shanghai, Peoples R China

[16] F Hoffmann Roche Ltd, Basel, Switzerland

[17] Genentech Inc, San Francisco, CA USA

[18] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-174209

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：6

共 50 条

[21] Phase Ib/II trial of polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed/refractory follicular lymphoma: primary analysis of the full efficacy population
Diefenbach, C. S.
McMillan, A.
Kahl, B. S.
Miall, F.
Banerjee, L.
Briones, J.
Cordoba, R.
Abrisqueta, P.
Hirata, J.
Chang, Y.
Musick, L.
BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 113 - 114
[22] Polatuzumab Vedotin in Relapsed and Refractory (r/r) Large B-Cell Lymphoma (LBCL): Real-World Data of the German National Compassionate Use Program (CUP)
Liebers, Nora
Duell, Johannes
Norenberg, Daniel
Kaebisch, Eva
Kerkhoff, Andrea
Acker, Fabian
Fuhrmann, Stephan
Leng, Corinna
Welslau, Manfred
Chemnitz, Jens
Middeke, Jan Moritz
Weber, Thomas
Trappe, Ralf Ulrich
Pfannes, Roald
Liersch, Ruediger
Spoer, Christian
Gebauer, Niklas
Fuxius, Stefan
Caille, Leandra
Pott, Christiane
Koenecke, Christian
Holtick, Udo
Geer, Thomas
Keller, Ulrich
Claus, Rainer
Mougiakakos, Dimitrios
Mayer, Stephanie
Huttmann, Andreas
Trummer, Arne
Wulf, Gerald
Brunnberg, Uta
Bullinger, Lars
Hess, Georg
Mueller-Tidow, Carsten
Glass, Bertram
Lenz, Georg
Dreger, Peter
Dietrich, Sascha
BLOOD, 2020, 136
[23] Real Event Analysis of the Efficacy and Safety of Polatuzumab Vedotin Combination Regimen in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Shi, Yuanfei
Xu, Yi
Wang, Jinghan
Zheng, Xiaolong
Li, Xueying
Jin, Jie
Tong, Hongyan
Xie, Wanzhuo
BLOOD, 2023, 142
[24] POLARGO: Randomized Phase III study of polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin (R-GemOx) in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
Haioun, Corinne
Matasar, Matthew J.
Sancho, Juan-Manuel
Viardot, Andreas
Hernandez, Juana
Perretti, Thomas
McMillan, Andrew
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[25] POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB (POLA plus BR) IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL): UPDATED RESULTS OF A PHASE IB/II RANDOMIZED STUDY AND PRELIMINARY RESULTS OF A SINGLE ARM EXTENSION
Pinto, A.
Sehn, L. H.
Hertzberg, M.
Opat, S.
Herrera, A. F.
Assouline, S.
Flowers, C. R.
Kim, T. M.
McMillan, A.
Ozcan, M.
Safar, V.
Salles, G.
Musick, L.
Hirata, J.
Chang, Y. M.
Ku, G.
Matasar, M. J.
HAEMATOLOGICA, 2021, 106 (10) : 69 - 69
[26] Polatuzumab Vedotin Combined with Bendamustine (B) and Rituximab (R) or Obinutuzumab (G) in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study
Herrera, Alex F.
Matasar, Matthew J.
Assouline, Sarit
Kamdar, Manali
Mehta, Amitkumar
Fleury, Isabelle
Kim, Won Seog
Kim, Tae Min
Bosch, Francesc
Radford, John A.
Bu, Lilian
Hong, Wan-Jen
Sehn, Laurie H.
BLOOD, 2016, 128 (22)
[27] Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial
Budde, Lihua E.
Olszewski, Adam J.
Assouline, Sarit
Lossos, Izidore S.
Diefenbach, Catherine
Kamdar, Manali
Ghosh, Nilanjan
Moth, Dipenkumar
Sabry, Waleed
Naik, Seema
Mehta, Amitkumar U.
Nakhoda, Shazia K.
Smith, Stephen D.
Dorritie, Kathleen
Jia, Ting
Pham, Song
Huw, Ling-Yuh
Jing, Jing
Wu, Hao
Ead, Wahib S.
To, Iris
Batlevi, Connie Lee
Wei, Michael C.
Chavez, Julio C.
NATURE MEDICINE, 2024, 30 (01) : 229 - +
[28] Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study
Flowers, Christopher R.
Matasar, Matthew J.
Herrera, Alex F.
Hertzberg, Mark
Assouline, Sarit
Demeter, Judit
Mcmillan, Andrew
Mehta, Amitkumar
Opat, Stephen
Trneny, Marek
Musick, Lisa
Hirata, Jamie
Yang, Annie
Sehn, Laurie H.
HAEMATOLOGICA, 2024, 109 (04) : 1194 - 1205
[29] Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial
Lihua E. Budde
Adam J. Olszewski
Sarit Assouline
Izidore S. Lossos
Catherine Diefenbach
Manali Kamdar
Nilanjan Ghosh
Dipenkumar Modi
Waleed Sabry
Seema Naik
Amitkumar Mehta
Shazia K. Nakhoda
Stephen D. Smith
Kathleen Dorritie
Ting Jia
Song Pham
Ling-Yuh Huw
Jing Jing
Hao Wu
Wahib S. Ead
Iris To
Connie Lee Batlevi
Michael C. Wei
Julio C. Chavez
Nature Medicine, 2024, 30 : 229 - 239
[30] Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study
Flowers, Christopher R.
Matasar, Matthew J.
Herrera, Alex F.
Hertzberg, Mark
Assouline, Sarit
Demeter, Judit
Mcmillan, Andrew
Mehta, Amitkumar
Opat, Stephen
Trneny, Marek
Musick, Lisa
Hirata, Jamie
Yang, Annie
Sehn, Laurie H.
REVISTA CHILENA DE LITERATURA, 2024, (109): : 1194 - 1205

← 1 2 3 4 5 →